The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C

Clinical and Developmental Immunology

Volumn 2012, Issue , 2012, Pages

  Bellanti, F ^a   Vendemiale, G ^a,b   Altomare, E ^a   Serviddio, G ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BOCEPREVIR; INTERFERON RECEPTOR; INTERLEUKIN 28A; INTERLEUKIN 28B; INTERLEUKIN 29; PEGINTERFERON; PEGINTERFERON LAMBDA; RIBAVIRIN; TELAPREVIR; ANTIVIRUS AGENT; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ANEMIA; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; BLOOD TOXICITY; DISEASE COURSE; FATIGUE; FEVER; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HEREDITY; HUMAN; HYPERTRANSAMINASEMIA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT DURATION; DRUG EFFECT; GENETICS; IMMUNOLOGY; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERLEUKINS; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 84866178019     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2012/849373     Document Type: Review

References (89)

1. Lavanchy D., Evolving epidemiology of hepatitis C virus. Clinical Microbiology and Infection 2011 17 2 107 115 2-s2.0-78751621217 10.1111/j.1469-0691.2010.03432.x
2. Shepard C. W., Finelli L., Alter M. J., Global epidemiology of hepatitis C virus infection. Lancet Infectious Diseases 2005 5 9 558 567 2-s2.0-23944506014 10.1016/S1473-3099(05)70216-4 (Pubitemid 41196755)
3. Rauch A., Rohrbach J., Bochud P. Y., The recent breakthroughs in the understanding of host genomics in hepatitis C. European Journal of Clinical Investigation 2010 40 10 950 959 2-s2.0-77956547987 10.1111/j.1365-2362.2010. 02337.x
4. Alberti A., Vario A., Ferrari A., Pistis R., Review article: chronic hepatitis Cnatural history and cofactors. Alimentary Pharmacology and Therapeutics 2005 22 supplement 2 74 78 2-s2.0-27644517886 (Pubitemid 41564389)
5. Manns M. P., Cornberg M., Wedemeyer H., Current and future treatment of hepatitis C. Indian Journal of Gastroenterology 2001 20 supplement 1 C47 C51 2-s2.0-0035082609 (Pubitemid 32246282)
6. Fried M. W., Shiffman M. L., Reddy K. R., Smith C., Marinos G., Goncales J. F. L., Häussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. The New England Journal of Medicine 2002 347 13 975 982 2-s2.0-0037179698 10.1056/NEJMoa020047
7. Muir A. J., Bornstein J. D., Killenberg P. G., Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. The New England Journal of Medicine 2004 350 22 2265 2271 2-s2.0-2442665224 10.1056/NEJMoa032502 (Pubitemid 38669209)
8. Kau A., Vermehren J., Sarrazin C., Treatment predictors of a sustained virologic response in hepatitis B and C. Journal of Hepatology 2008 49 4 634 651 2-s2.0-50649112802 10.1016/j.jhep.2008.07.013
9. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., Nakagawa M., Korenaga M., Hino K., Hige S., Ito Y., Mita E., Tanaka E., Mochida S., Murawaki Y., Honda M., Sakai A., Hiasa Y., Nishiguchi S., Koike A., Sakaida I., Imamura M., Ito K., Yano K., Masaki N., Sugauchi F., Izumi N., Tokunaga K., Mizokami M., Genome-wide association of IL28B with response to pegylated interferon- α and ribavirin therapy for chronic hepatitis C. Nature Genetics 2009 41 10 1105 1109 2-s2.0-70349533037 10.1038/ng.449
10. Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M. L., Bassendine M., Spengler U., Dore G. J., Powell E., Riordan S., Sheridan D., Smedile A., Fragomeli V., Müller T., Bahlo M., Stewart G. J., Booth D. R., George J., IL28B is associated with response to chronic hepatitis C interferon- α and ribavirin therapy. Nature Genetics 2009 41 10 1100 1104 2-s2.0-70349548852 10.1038/ng.447
11. Ge D., Fellay J., Thompson A. J., Simon J. S., Shianna K. V., Urban T. J., Heinzen E. L., Qiu P., Bertelsen A. H., Muir A. J., Sulkowski M., McHutchison J. G., Goldstein D. B., Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009 461 7262 399 401 2-s2.0-70349292099 10.1038/nature08309
12. Rauch A., Kutalik Z., Descombes P., Cai T., Di Iulio J., Mueller T., Bochud M., Battegay M., Bernasconi E., Borovicka J., Colombo S., Cerny A., Dufour J., Furrer H., Günthard H. F., Heim M., Hirschel B., Malinverni R., Moradpour D., Müllhaupt B., Witteck A., Beckmann J. S., Berg T., Bergmann S., Negro F., Telenti A., Bochud P. Y., Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010 138 4 1338 1345 2-s2.0-77949831342 10.1053/j.gastro.2009.12.056
13. Kotenko S. V., Gallagher G., Baurin V. V., Lewis-Antes A., Shen M., Shah N. K., Langer J. A., Sheikh F., Dickensheets H., Donnelly R. P., IFN- λ s mediate antiviral protection through a distinct class II cytokine receptor complex. Nature Immunology 2003 4 1 69 77 2-s2.0-0037243222 10.1038/ni875 (Pubitemid 36109115)
14. Sheppard P., Kindsvogel W., Xu W., IL-28, IL-29 and their class II cytokine receptor IL-28R. Nature Immunology 2003 4 1 63 68 10.1038/ni873 (Pubitemid 36104710)
15. Lasfar A., Abushahba W., Balan M., Cohen-Solal K. A., Interferon lambda: a new sword in cancer immunotherapy. Clinical and Developmental Immunology 2011 2011 11 349575 10.1155/2011/349575
16. Witte K., Gruetz G., Volk H. D., Looman A. C., Asadullah K., Sterry W., Sabat R., Wolk K., Despite IFN- receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: Implications for therapeutic applications of these cytokines. Genes and Immunity 2009 10 8 702 714 2-s2.0-73849130903 10.1038/gene.2009.72
17. Pagliaccetti N. E., Robek M. D., Interferon- λ in HCV infection and therapy. Viruses 2010 2 8 1589 1602 2-s2.0-79952172888 10.3390/v2081589
18. Rodríguez J. L., Sandoval J., Serviddio G., Sastre J., Morante M., Perrelli M. G., Martínez-Chantar M. L., Via J., Via J. R., Mato J. M., Ávila M. A., Franco L., López-Rodas G., Torres L., Id2 leaves the chromatin of the E2F4-p130-controlled c-myc promoter during hepatocyte priming for liver regeneration. Biochemical Journal 2006 398 3 431 437 2-s2.0-33748753062 10.1042/BJ20060380 (Pubitemid 44453387)
19. Donnelly R. P., Dickensheets H., O'Brien T. R., Interferon-lambda and therapy for chronic hepatitis C virus infection. Trends in Immunology 2011 32 9 443 450 2-s2.0-79960991473 10.1016/j.it.2011.07.002
20. Burke J. D., Fish E. N., Antiviral strategies: the present and beyond. Current Molecular Pharmacology 2009 2 1 32 39 2-s2.0-70350681648 10.2174/1874467210902010032
21. Kelly C., Klenerman P., Barnes E., Interferon lambdas: the next cytokine storm. Gut 2011 60 9 1284 1293 2-s2.0-79551690037 10.1136/gut.2010.222976
22. Coccia E. M., Severa M., Giacomini E., Monneron D., Remoli M. E., Julkunen I., Cella M., Lande R., Uzé G., Viral infection and toll-like receptor agonists induce a differential expression of type I and λ interferons in humans plasmacytoid and monocyte-derived dendritic cells. European Journal of Immunology 2004 34 3 796 805 2-s2.0-1642370060 10.1002/eji.200324610 (Pubitemid 39255927)
23. Robek M. D., Boyd B. S., Chisari F. V., Lambda interferon inhibits hepatitis B and C virus replication. Journal of Virology 2005 79 6 3851 3854 2-s2.0-14744276042 10.1128/JVI.79.6.3851-3854.2005 (Pubitemid 40327973)
24. Ank N., West H., Bartholdy C., Eriksson K., Thomsen A. R., Paludan S. R., Lambda interferon (IFN- λ), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. Journal of Virology 2006 80 9 4501 4509 2-s2.0-33646185492 10.1128/JVI.80.9.4501-4509.2006
25. Doyle S. E., Schreckhise H., Khuu-Duong K., Henderson K., Rosler R., Storey H., Yao L., Liu H., Barahmand-Pour F., Sivakumar P., Chan C., Birks C., Foster D., Clegg C. H., Wietzke-Braun P., Mihm S., Klucher K. M., Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Journal of Hepatology 2006 44 4 896 906 2-s2.0-33750631014 10.1002/hep.21312 (Pubitemid 46489554)
26. Marcello T., Grakoui A., Barba-Spaeth G., Machlin E. S., Kotenko S. V., Macdonald M. R., Rice C. M., Interferons α and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006 131 6 1887 1898 2-s2.0-33845605155 10.1053/j.gastro.2006.09.052 (Pubitemid 44958521)
27. Zhang L., Jilg N., Shao R. X., Lin W., Fusco D. N., Zhao H., Goto K., Peng L. F., Chen W. C., Chung R. T., IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. Journal of Hepatology 2011 55 2 289 298 2-s2.0-79960462492 10.1016/j.jhep.2010.11.019
28. Ramos E. L., Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C. Journal of Interferon and Cytokine Research 2010 30 8 591 595 2-s2.0-77955889460 10.1089/jir.2010.0066
29. Muir A. J., Shiffman M. L., Zaman A., Yoffe B., De La Torre A., Flamm S., Gordon S. C., Marotta P., Vierling J. M., Lopez-Talavera J. C., Byrnes-Blake K., Fontana D., Freeman J., Gray T., Hausman D., Hunder N. N., Lawitz E., Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Journal of Hepatology 2010 52 3 822 832 2-s2.0-77955873433 10.1002/hep.23743
30. Siebler J., Wirtz S., Weigmann B., Atreya I., Schmitt E., Kreft A., Galle P. R., Neurath M. F., IL-28A is a key regulator of T-cell-mediated liver injury via the T-box transcription factor T-bet. Gastroenterology 2007 132 1 358 371 2-s2.0-33846197963 10.1053/j.gastro.2006.10.028 (Pubitemid 46108741)
31. Dellgren C., Gad H. H., Hamming O. J., Melchjorsen J., Hartmann R., Human interferon- λ 3 is a potent member of the type III interferon family. Genes and Immunity 2009 10 2 125 131 2-s2.0-61849126356 10.1038/gene.2008.87
32. Morrow M. P., Pankhong P., Laddy D. J., Schoenly K. A., Yan J., Cisper N., Weiner D. B., Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 2009 113 23 5868 5877 2-s2.0-67651115867 10.1182/blood-2008-11-190520
33. Honda M., Sakai A., Yamashita T., Nakamoto Y., Mizukoshi E., Sakai Y., Yamashita T., Nakamura M., Shirasaki T., Horimoto K., Tanaka Y., Tokunaga K., Mizokami M., Kaneko S., Kagaya T., Arai K., Kakinoki K., Kawaguchi K., Takatori H., Sunakosaka H., Nakahama T., Kamiyamamoto S., Takemori Y., Oguri H., Noda Y., Ogino H., Hinoue Y., Minouchi K., Hirai N., Sugimoto T., Adachi K., Nakamura Y., Unoura M., Nishino R., Morimoto H., Ohta H., Tsuji H., Iwata A., Terasaki S., Wakabayashi T., Shirota Y., Urabe T., Kawai H., Mizuno Y., Kameda S., Miyamori H., Fuchizaki U., Shyugo H., Osaka H., Matsushita E., Katou Y., Tanaka N., Notsumata K., Kumagai M., Yoneshima M., Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010 139 2 499 509 2-s2.0-77955475888 10.1053/j.gastro.2010.04.049
34. Urban T. J., Thompson A. J., Bradrick S. S., Fellay J., Schuppan D., Cronin K. D., Hong L., McKenzie A., Patel K., Shianna K. V., McHutchison J. G., Goldstein D. B., Afdhal N., IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Journal of Hepatology 2010 52 6 1888 1896 2-s2.0-78649608515 10.1002/hep.23912
35. Scott J., Holte S., Urban T., Burgess C., Coppel E., Wang C., Corey L., McHutchison J., Goldstein D., IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult-to-treat hepatitis C virus infection. Journal of Infectious Diseases 2011 204 3 419 425 2-s2.0-79960150527 10.1093/infdis/jir264
36. Gaudieri S., Lucas M., Lucas A., Genetic variations in IL28B and allergic disease in children. PLoS ONE 2012 7 1, article e30607 10.1371/journal.pone. 0030607
37. Ren S., Lu J., Du X., Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma. Cancer Immunology, Immunotherapy. In press
38. Lotrich F. E., Loftis J. M., Ferrell R. E., Rabinovitz M., Hauser P., IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy. Journal of Interferon and Cytokine Research 2011 31 3 331 336 2-s2.0-79952304368 10.1089/jir.2010.0074
39. Li J. H., Lao X. Q., Tillmann H. L., Rowell J., Patel K., Thompson A., Suchindran S., Muir A. J., Guyton J. R., Gardner S. D., McHutchison J. G., McCarthy J. J., Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Journal of Hepatology 2010 51 6 1904 1911 2-s2.0-77952730427 10.1002/hep.23592
40. Tillmann H. L., Patel K., Muir A. J., Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. Journal of Hepatology 2011 55 6 1195 1200
41. Clark P. J., Thompson A. J., Zhu Q., The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection. Digestive Diseases and Sciences. In press
42. Mangia A., Thompson A. J., Santoro R., Piazzolla V., Tillmann H. L., Patel K., Shianna K. V., Mottola L., Petruzzellis D., Bacca D., Carretta V., Minerva N., Goldstein D. B., McHutchison J. G., An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010 139 3 821 827 2-s2.0-77956134252 10.1053/j.gastro.2010.05.079
43. Pineda J. A., Caruz A., Rivero A., Neukam K., Salas I., Camacho Á.., Palomares J. C., Mira J. A., Martínez A., Roldán C., De La Torre J., Macías J., Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clinical Infectious Diseases 2010 51 7 788 795 2-s2.0-77957825574 10.1086/656235
44. Sarrazin C., Susser S., Doehring A., Lange C. M., Müller T., Schlecker C., Herrmann E., Lötsch J., Berg T., Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. Journal of Hepatology 2011 54 3 415 421 2-s2.0-79951679619 10.1016/j.jhep.2010.07.041
45. Labarga P., Barreiro P., Mira J. A., Impact of IL28B polymorphisms on response to peginterferon plus ribavirin in HIV-HCV coinfected patients with prior non-response or relapse. AIDS. In press
46. Asselah T., De M. S., Broet P., IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. Journal of Hepatology 2012 56 3 527 532 10.1016/j.jhep.2011.09.008
47. Chu T. W., Kulkarni R., Gane E. J., Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology 2012 142 4 790 795
48. Naggie S., Osinusi A., Katsounas A., Dysregulation of innate immunity in HCV genotype 1 IL28B unfavorable genotype patients: impaired viral kinetics and therapeutic response. Journal of Hepatology. In press
49. Rembeck K., Alsio A., Christensen P. B., Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. PLoS ONE 2012 7 1, article e29370
50. Rembeck K., Westin J., Lindh M., Hellstrand K., Norkrans G., Lagging M., Association between IL28B-related genetic variants and liver histopathology differs between hcv genotypes. Journal of Hepatology. In press
51. Nattermann J., Vogel M., Nischalke H. D., Danta M., Mauss S., Stellbrink H. J., Baumgarten A., Mayr C., Bruno R., Tural C., Klausen G., Clotet B., Naumann U., Lutz T., Rausch M., Schewe K., Bienek B., Haerter G., Sauerbruch T., Rockstroh J. K., Spengler U., Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C. Journal of Infectious Diseases 2011 203 5 595 601 2-s2.0-79751511058 10.1093/infdis/jiq098
52. Clausen L. N., Astvad K., Ladelund S., Larsen M. V., Schonning K., Benfield T., Hepatitis C viral load, genotype 3 and IL28B CC genotype predict mortality in HIV and hepatitis C coinfected individuals. AIDS. In press
53. Parczewski M., Bander D., Leszczyszyn-Pynka M., Urbanska A., Socha L., Boron-Kaczmarska A., IL28B CC genotype is associated with higher all-cause mortality in antiretroviral-treated HIV-infected patients. AIDS. In press
54. Thomas D. L., Thio C. L., Martin M. P., Qi Y., Ge D., Ohuigin C., Kidd J., Kidd K., Khakoo S. I., Alexander G., Goedert J. J., Kirk G. D., Donfield S. M., Rosen H. R., Tobler L. H., Busch M. P., McHutchison J. G., Goldstein D. B., Carrington M., Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009 461 7265 798 801 2-s2.0-70349966196 10.1038/nature08463
55. Tillmann H. L., Thompson A. J., Patel K., Wiese M., Tenckhoff H., Nischalke H. D., Lokhnygina Y., Kullig U., Göbel U., Capka E., Wiegand J., Schiefke I., Güthoff W., Grüngreiff K., König I., Spengler U., McCarthy J., Shianna K. V., Goldstein D. B., McHutchison J. G., Timm J., Nattermann J., A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010 139 5 1586 1592 2-s2.0-78049469161 10.1053/j.gastro.2010.07.005
56. Knapp S., Warshow U., Ho K. M. A., Hegazy D., Little A., Fowell A., Alexander G., Thursz M., Cramp M., Khakoo S. I., A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection. Gastroenterology 2011 141 1 320 325 2-s2.0-79959962743 10.1053/j.gastro.2011.04.005
57. Lange C. M., Moradpour D., Doehring A., Lehr H. A., Müllhaupt B., Bibert S., Bochud P. Y., Antonino A. T., Pascual M., Farnik H., Shi Y., Bechstein W. O., Moench C., Hansmann M. L., Sarrazin C., Lötsch J., Zeuzem S., Hofmann W. P., Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. Journal of Hepatology 2011 55 2 322 327 2-s2.0-79960452181 10.1016/j.jhep.2010.10.037
58. Veldt B. J., Duarte-Rojo A., Thompson A. J., Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. American Journal of Transplantation 2012 12 3 737 744 10.1111/j.1600-6143.2011.03843.x
59. Kawaoka T., Hayes C. N., Ohishi W., Ochi H., Maekawa T., Abe H., Tsuge M., Mitsui F., Hiraga N., Imamura M., Takahashi S., Kubo M., Tsunoda T., Nakamura Y., Kumada H., Chayama K., Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. Journal of Hepatology 2011 54 3 408 414 2-s2.0-79951675730 10.1016/j.jhep.2010.07.032
60. Hsu C. S., Hsu S. J., Chen H. C., Tseng T. C., Liu C. H., Niu W. F., Jeng J., Liu C. J., Lai M. Y., Chen P. J., Kao J. H., Chen D. S., Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proceedings of the National Academy of Sciences of the United States of America 2011 108 9 3719 3724 2-s2.0-79952759141 10.1073/pnas.1100349108
61. Chen Y., Xu H. X., Wang L. J., Liu X. X., Mahato R. I., Zhao Y. R., Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-alpha and ribavirin. Alimentary Pharmacology & Therapeutics 2012 36 2 91 103 10.1111/j.1365-2036.2012.05131. x
62. Fukuhara T., Taketomi A., Motomura T., Okano S., Ninomiya A., Abe T., Uchiyama H., Soejima Y., Shirabe K., Matsuura Y., Maehara Y., Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010 139 5 1577 1585 2-s2.0-78049470128 10.1053/j.gastro.2010.07.058
63. Aparicio E., Parera M., Franco S., Pérez-Alvarez N., Tural C., Clotet B., Martínez M. A., IL28B SNP rs8099917 is strongly associated with pegylated interferon- α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS ONE 2010 5 10, article e13771 2-s2.0-78149427491 10.1371/journal.pone.0013771
64. Aizawa Y., Yohizawa K., Aida Y., Ishiguro H., Abe H., Tsubota A., Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C. Molecular and Cellular Biochemistry 2012 360 1-2 9 14
65. van den Berg C. H., Grady B. P., Schinkel J., Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS ONE 2011 6 11, article e27555
66. Bochud P. Y., Bibert S., Kutalik Z., IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Journal of Hepatology 2012 55 2 384 394 10.1002/hep.24678
67. Moghaddam A., Melum E., Reinton N., Ring-Larsen H., Verbaan H., Bjoro K., Dalgard O., IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Journal of Hepatology 2011 53 3 746 754 2-s2.0-79952214262 10.1002/hep.24154
68. Arends J. E., Fransen J. H., Hoepelman A. I., van Baarle D., Association between IL28B polymorphisms and first-phase viral load decrease in chronic hepatitis C virus-infected patients treated with peginterferon alfa-2b/ribavirin. International Journal of Antimicrobial Agents 2011 38 6 538 539 10.1016/j.ijantimicag.2011.08.010
69. Rivero-Juarez A., Camacho E. A., Perez-Camacho I., Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4. Journal of Antimicrobial Chemotherapy 2012 67 1 202 205
70. Dahari H., Perelson A. S., Hepatitis C virus kinetics in chimeric mice during antiviral therapy. Journal of Hepatology 2007 46 6 2048 2049 2-s2.0-37749023086 10.1002/hep.21798
71. Hayes C. N., Kobayashi M., Akuta N., Suzuki F., Kumada H., Abe H., Miki D., Imamura M., Ochi H., Kamatani N., Nakamura Y., Chayama K., HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 2011 60 2 261 267 2-s2.0-78651107054 10.1136/gut.2010.223495
72. Lagging M., Askarieh G., Negro F., Bibert S., Söderholm J., Westin J., Lindh M., Romero A., Missale G., Ferrari C., Neumann A. U., Pawlotsky J. M., Haagmans B. L., Zeuzem S., Bochud P. Y., Hellstrand K., Response prediction in chronic hepatitis c by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS ONE 2011 6 2, article e17232 2-s2.0-79952097683 10.1371/journal.pone.0017232
73. Fattovich G., Covolo L., Bibert S., Askarieh G., Lagging M., Clément S., Malerba G., Pasino M., Guido M., Puoti M., Gaeta G. B., Santantonio T., Raimondo G., Bruno R., Bochud P. Y., Donato F., Negro F., IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Alimentary Pharmacology and Therapeutics 2011 33 10 1162 1172 2-s2.0-79954797695 10.1111/j.1365-2036.2011.04635.x
74. Beinhardt S., Aberle J. H., Strasser M., Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology 2012 142 1 78 85 10.1053/j.gastro.2011.09.039
75. Lin C. Y., Chen J. Y., Lin T. N., Jeng W. J., Huang C. H., Huang C. W., Chang S. W., Sheen I. S., IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS ONE 2011 6 3, article e18322 2-s2.0-79953298817 10.1371/journal.pone.0018322
76. Halfon P., Bourliere M., Ouzan D., A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus. European Journal of Gastroenterology & Hepatology 2011 23 10 931 935 10.1097/MEG.0b013e328349d0ef
77. Li S., Hu P., Zhang Q. Q., Liu Y. H., Hu H. D., Zhang D. Z., Ren H., Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: a meta-analysis. Hepatitis Monthly 2011 11 3 163 172 2-s2.0-79955582363
78. de Castellarnau M., Aparicio E., Parera M., Deciphering the interleukin 28B variants that better predict response to pegylated interferon-alpha and ribavirin therapy in HCV/HIV-1 coinfected patients. PLoS ONE 2012 7 2, article e31016
79. Fischer J., Bohm S., Scholz M., Combined effects of different IL28B gene variants onthe outcome of dual combination therapy in chronic HCV type 1 infection. Journal of Hepatology. In press
80. Suppiah V., Gaudieri S., Armstrong N. J., IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Medicine 2011 8 9, article e1001092
81. Dring M. M., Morrison M. H., McSharry B. P., Guinan K. J., Hagan R., O'Farrelly C., Gardiner C. M., Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection. Proceedings of the National Academy of Sciences of the United States of America 2011 108 14 5736 5741 2-s2.0-79955040564 10.1073/pnas.1016358108
82. Kramer B., Eisenhardt M., Glassner A., Do lambda-IFNs IL28A and IL28B act on human natural killer cells? Proceedings of the National Academy of Sciences of the United States of America 2011 108 34 E519 E520
83. Bacon B. R., Gordon S. C., Lawitz E., Marcellin P., Vierling J. M., Zeuzem S., Poordad F., Goodman Z. D., Sings H. L., Boparai N., Burroughs M., Brass C. A., Albrecht J. K., Esteban R., Boceprevir for previously treated chronic HCV genotype 1 infection. The New England Journal of Medicine 2011 364 13 1207 1217 2-s2.0-79953176289 10.1056/NEJMoa1009482
84. Zeuzem S., Andreone P., Pol S., Lawitz E., Diago M., Roberts S., Focaccia R., Younossi Z., Foster G. R., Horban A., Ferenci P., Nevens F., Müllhaupt B., Pockros P., Terg R., Shouval D., Van Hoek B., Weiland O., Van Heeswijk R., De Meyer S., Luo D., Boogaerts G., Polo R., Picchio G., Beumont M., Telaprevir for retreatment of HCV infection. The New England Journal of Medicine 2011 364 25 2417 2428 2-s2.0-79959381354 10.1056/NEJMoa1013086
85. Akuta N., Suzuki F., Hirakawa M., Kawamura Y., Yatsuji H., Sezaki H., Suzuki Y., Hosaka T., Kobayashi M., Kobayashi M., Saitoh S., Arase Y., Ikeda K., Chayama K., Nakamura Y., Kumada H., Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Journal of Hepatology 2010 52 2 421 429 2-s2.0-77955691994 10.1002/hep.23690
86. Jacobson I. M., McHutchison J. G., Dusheiko G., Di Bisceglie A. M., Reddy K. R., Bzowej N. H., Marcellin P., Muir A. J., Ferenci P., Flisiak R., George J., Rizzetto M., Shouval D., Sola R., Terg R. A., Yoshida E. M., Adda N., Bengtsson L., Sankoh A. J., Kieffer T. L., George S., Kauffman R. S., Zeuzem S., Telaprevir for previously untreated chronic hepatitis C virus infection. The New England Journal of Medicine 2011 364 25 2405 2416 2-s2.0-79959438789 10.1056/NEJMoa1012912
87. Poordad F., Bronowicki J. P., Gordon S. C., IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with boceprevir (Boc) combination therapy. Journal of Hepatology 2011 54 supplement 1 S6
88. Welsch C., Jesudian A., Zeuzem S., Jacobson I., New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 2012 61 supplement 1 i36 i46 10.1136/gutjnl-2012-302144
89. Lange C. M., Zeuzem S., IL28B single nucleotide polymorphisms in the treatment of hepatitis C. Journal of Hepatology 2011 55 3 692 701 2-s2.0-79958824451 10.1016/j.jhep.2011.03.006